Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with severe vulvovaginal candidiasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University Shenzhen Hospital
• Collaborators: Shanghai Shyndec Pharmaceutical Co., Ltd.; Shanghai Shyndec Pharmaceutical Co.,Ltd.
• Treatments: Fluconazole; Terconazole

Criteria

Inclusion Criteria:

• Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3) with a minimum VVC Composite Signs/Symptoms score of 7

• Subject completes the informed consent process

• Subject agrees to take study medication when scheduled

• Subject complies with all clinical trial instructions. Commits to all follow-up visits

• Subject agrees to abstain from sexual intercourse from the time of randomization through the first seven days immediately following treatment

Exclusion Criteria:

• had any other sexually transmitted disease or gynaecological abnormality requiring treatment

• had a disease known to predispose to candidiasis such as diabetes mellitus, or were receiving antibiotics or corticosteriods

• had used antifungal medication in the week before entry; or

• were expected to menstruate within seven days of the start of treatment

• infected more than one candida species